Intravenous Immunoglobulins in a Series of 32 Rare and Recalcitrant Immune Dermatoses
DOI:
https://doi.org/10.2340/00015555-3662Keywords:
intravenous immunoglobulin, dermatomyositis, autoimmune bullous dermatosis, vasculitis, Stevens-Johnson syndrome, pyoderma gangrenosumAbstract
Intravenous immunoglobulins are an effective and well-tolerated treatment option for immune dermatological diseases. However, they are primarily used to treat diseases with a severe course and are mostly used off-label. Therefore, it is important to document case series on the use of intravenous immunoglobulins in rare immune dermatological diseases. We present here 32 patients who were treated with intravenous immunoglobulins in our clinic between 2015 and 2020. The indications were dermatomyositis, including amyopathic and paraneoplastic forms, as well as overlap-syndromes (n?=?18), pemphigus vulgaris (n?=?2), mucous membrane pemphigoid (n?=?2), linear IgA dermatosis (n?=?1), necrotizing vasculitis (n?=?1), urticarial vasculitis (n?=?1), systemic scleroderma (n?=?1), Stevens-Johnson syndrome (n?=?1), pyoderma gangrenosum (n?=?3), and livedoid vasculopathy (n?=?2). The data from this case series confirm the efficacy and tolerability of intravenous immunoglobulins as an adjuvant treatment option for rare therapy-resistant immune dermatoses.Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Roberta Scarpone, Katharina Meier, Kamran Ghoreschi, Margitta Worm
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.